HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ashley Yeo

Executive Editor, MTI; Medtech Editor, In Vivo

London, UK

Ashley has reported on health care market issues with Citeline and legacy companies since 1988, initially as a linguist on the France and Germany desk and later becoming editor of three titles. Two publications are his current focus for written and multimedia (panel moderating and podcasts) content: In Vivo (global medtech market access); and Medtech Insight (regulation and policy content for the UK, European and Asia markets).

Latest From Ashley Yeo

CMS Incubator Helps ‘equIP’ Health Care Innovators With AI Power

The trend among device innovators to focus on diagnostic technologies that improve imaging, offer better visualization of tissues and avoid the need for biopsies is well noted by full-service law firm CMS. Its equIP program supports many start-ups incorporating AI into products and development processes.

Innovation Medical Device

Launch Of Team-AB Offers United Voice For UK Approved Bodies

Forum officially unveiled on 19 February to represent growing band of organizations designated against the UKCA mark.

United Kingdom Regulation

Prostate Screening: UK Industry Body Explores Role In Study, Points To Growing Diagnostics Remit

Early diagnosis information is central to disease detection and will reduce treatment costs overall, says Nishan Sunthares, who heads the Association of British HealthTech Industries’ work on diagnostic technologies including IVDs.

United Kingdom Policy

UK Approved Body Capacity Rises But Not For IVDs

While Great Britain is on the cusp of a major program of laying the foundations of its agile, post-EU medtech regulatory system, uncertainty persists over the future role and remit of local CABs.

United Kingdom Regulation

Philips Commits To ESG And AI While Servicing Respironics Recall Priority

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Leadership Restructuring

Philips Doubles Down On ESG And AI While Servicing Respironics Recall Priority

Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.

Leadership Restructuring
See All
UsernamePublicRestriction

Register